Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Short-term Investments (2024 - 2025)

BioNexus Gene Lab's Short-term Investments history spans 2 years, with the latest figure at $1.7 million for Q3 2025.

  • For Q3 2025, Short-term Investments changed N/A year-over-year to $1.7 million; the TTM value through Sep 2025 reached $1.7 million, changed N/A, while the annual FY2024 figure was $2.8 million, N/A changed from the prior year.
  • Short-term Investments for Q3 2025 was $1.7 million at BioNexus Gene Lab, down from $2.2 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $2.8 million in Q4 2024 and bottomed at $1.7 million in Q3 2025.